Brind.

Director Michael R. Hayden purchased stock in Ionis Pharmaceuticals as an insider investment.

1 report, 1 independent Updated Aug 3

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Ionis PharmaceuticalsMichael R. Hayden

Keep exploring

The entities involved

Ionis Pharmaceuticals
American pharmaceutical company
- GSK and Ionis Pharmaceuticals co-developed the bepirovirsen drug for hepatitis B.Sat 18:16

Related events

Geode Capital Management lifted its position in Ionis Pharmaceuticals stock, which is listed on Nasdaq and filed with the SEC.Sep 3

Coverage

Newest first; wire copies grouped

Aug 3fool.com